Le Journal des entreprises – Dianosic in the press

540 250 Philippe Bastide


Dianosic closes first funding round of €1.5M

540 250 Philippe Bastide

Dianosic obtains CE marking for CAVI-T, medical device for treating intranasal bleeding

540 250 Philippe Bastide

This critical milestone will enable Dianosic to start marketing its minimally invasive solution in Europe and continue developing other innovative ENT solutions


Strasbourg, France, March 10, 2020 :

Dianosic, a Strasbourg-based startup specializing in innovative solutions for ear, nose, and throat (ENT) conditions, today announces that it has obtained CE marking for CAVI-TTM, a low-pressure asymmetric balloon for treating spontaneous and post-operative intranasal bleeding. This class IIa certification, obtained at the end of February, will enable the company to begin marketing the device in Europe.

CAVI-T, which is designed to treat intranasal bleeding (epistaxis), is patented in France and will be soon in Europe, the United States, Japan and China. It is the first asymmetric intranasal balloon that stops bleeding by applying low-force compression while adapting to the anatomy of the nasal fossa. The balloon can remain in place for one to three days.

At present, this atraumatic, easy-to-use medical device is aimed primarily at hospitals. A pilot study between April and June 2019, led by Professor Christian Debry, Head of the ENT department at Strasbourg University Hospital, demonstrated its safety and efficacy. The balloon was effective in stopping bleeding in 90% of patients and significantly improved their quality of life. This feasibility study also demonstrated the good safety profile of CAVI-T, with a mean pain score on product insertion and removal of 4.7 and 1.6 respectively. (Evaluated on a Visual Analogue Scale ranging from 1 to 10).

“Obtaining CE marking is an important recognition of Dianosic’s expertise and the ability of its team to conceive and develop innovative products to treat ENT disorders,” said Marc Augustin, President of Dianosic.

“Following this major step in our development, we are ready to prepare the commercial launch of the product in Europe, which is expected to take place during the second quarter of 2020. Dianosic’s entry into the market represents a prime opportunity for growth, with the potential to reach close to five million patients across Europe and the United States,” said Philippe Bastide, CEO of Dianosic.

More info at:


About Dianosic SAS

Dianosic develops innovative solutions for the management of ENT conditions.
Incubated by SEMIA, named ‘incubator of excellence’ for the Grand Est region in January 2018, Dianosic is led by company President Marc Augustin and CEO Philippe Bastide. Professor Christian Debry, Head of the ENT department at Strasbourg University Hospital Center, acts as a scientific advisor to the company.
Dianosic was a winner at i-Lab 2019, an innovation contest run by Bpifrance and the Ministry of Higher Education, Research and Innovation. Dianosic was also selected to take part in a Soft-Landing program in Boston, MA in September 2019. This program was organized by Strasbourg Eurométropole and Innouvo in partnership with Cajuba Finance.
Founded in July 2017 and based in Strasbourg, Dianosic aims to become a European leader in the management of intranasal bleeding and chronic sinusitis with its active, long-term resorbable treatment

Victor Moreau joins Dianosic as R&D engineer

540 250 Philippe Bastide

Victor Moreau joins Dianosic as R&D engineer to support the development of its innovative solution in the treatment of chronic sinusitis.


Dianosic is committed to the development of disruptive technologies in the field of Ear Nose and Throat (#ENT) and focuses more specifically on the nasal cavity. As we pursue our efforts to bring our disruptive solution to life in the field of #chronicsinusitis, we are glad to announce that Victor Moreau is joining the team as R&D Engineer.

Victor brings a solid knowledge in the formulation of resorbable polymers for biomedical applications. Victor also worked as a Quality Assistant at DEDIENNE SANTE. Those competencies will greatly contribute to the progress of our project. Victor, along with Sarah Zahouani (CTO, Dianosic) will work closely with the Polymers for Health and Biomaterials team, which has a renowned expertise in bioresorbable polymers. We’d like to thank Xavier Garric (Head of the, PHBM), the CNRS – Centre national de la recherche scientifique, the Université de Montpellier and the ENSCM for making this fantastic partnership, in which Victor will have a central position, a reality.

We look forward to having this team transform the way patients with chronic sinusitis will be treated in the future and pave the way for Dianosic upcoming successes.


Victor, a warm welcome to you!


Jacques Penicaud accompany Dianosic

540 250 Philippe Bastide

Jacques Penicaud accompany Dianosic to prepare for launch of its first product (CAVI-T) for the treatment of intranasal bleeding (epistaxis)


As dianosic continues to make headway towards commercialization of its CAVI-T solution in intranasal bleeding, we are excited to inform you that Jacques PENICAUD will support us in preparing the launch of this innovative product. 

During his career, Jacques held different positions at Johnson & Johnson ranging from Financial controller to Sales Director and Business Unit Director for the Medical Devices segment (Advanced Wound Care, Ethicon Biosurgery, Mitek and Advanced Sterilization Products). Jacques then pursued an external opportunity as the CEO of STERIENCE (sterilization business) before joining Abbott Vascular as General Manager. 

Jacques will leverage his huge experience in the successful launch of disruptive medical technologies to strategize commercialization efforts for our CAVI-T solution. 


Jacques, we look forward to disrupting the market together!! ????

#epistaxis #nosebleeds #ENT